Literature DB >> 20347032

Concomitant detection of beta-amyloid peptides with N-terminal truncation and different C-terminal endings in cortical plaques from cases with Alzheimer's disease, senile monkeys and triple transgenic mice.

Wolfgang Härtig1, Simone Goldhammer, Ute Bauer, Florian Wegner, Oliver Wirths, Thomas A Bayer, Jens Grosche.   

Abstract

The disturbed metabolism of beta-amyloid peptides generated from amyloid precursor protein is widely considered as a main factor during the pathogenesis of Alzheimer's disease. A neuropathological hallmark in the brains from cases with Alzheimer's disease are senile plaques mainly composed of hardly soluble beta-amyloid peptides comprising up to 43 amino acids. Age-dependent cortical beta-amyloidosis was also shown in several transgenic mice and old individuals from various mammalian species, e.g., non-human primates. Beta-amyloid(1-42) is believed to be the main component in the core of senile plaques, whereas less hydrophobic beta-amyloid(1-40) predominantly occurs in the outer rim of plaques. Amino-terminally truncated pyroglutamyl-beta-amyloid(pE3-x) was recently found to be a beta-amyloid species of high relevance to the progression of the disease. While a few biochemical studies provided data on the co-occurrence of several beta-amyloid forms, their concomitant histochemical detection is still lacking. Here, we present a novel triple immunofluorescence labelling of amino- and differently carboxy-terminally truncated beta-amyloid peptides in cortical plaques from a case with Alzheimer's disease, senile macaques and baboons, and triple transgenic mice with age-dependent beta-amyloidosis and tau hyperphosphorylation. Additionally, beta-amyloid(pE3-x) and total beta-amyloid were concomitantly detected with beta-amyloid peptides ending with amino acid 40 or 42, respectively. Simultaneous staining of several beta-amyloid species reveals for instance vascular amyloid containing beta-amyloid(pE3-x) in Alzheimer's disease and monkeys, and may contribute to the further elucidation of beta-amyloidosis in neurodegenerative disorders and animal models. 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20347032     DOI: 10.1016/j.jchemneu.2010.03.006

Source DB:  PubMed          Journal:  J Chem Neuroanat        ISSN: 0891-0618            Impact factor:   3.052


  11 in total

1.  β-Secretase-1 elevation in aged monkey and Alzheimer's disease human cerebral cortex occurs around the vasculature in partnership with multisystem axon terminal pathogenesis and β-amyloid accumulation.

Authors:  Yan Cai; Kun Xiong; Xue-Mei Zhang; Huaibin Cai; Xue-Gang Luo; Jia-Chun Feng; Richard W Clough; Robert G Struble; Peter R Patrylo; Yaping Chu; Jeffrey H Kordower; Xiao-Xin Yan
Journal:  Eur J Neurosci       Date:  2010-08-18       Impact factor: 3.386

Review 2.  Recent rodent models for Alzheimer's disease: clinical implications and basic research.

Authors:  Nady Braidy; Pablo Muñoz; Adrian G Palacios; Gloria Castellano-Gonzalez; Nibaldo C Inestrosa; Roger S Chung; Perminder Sachdev; Gilles J Guillemin
Journal:  J Neural Transm (Vienna)       Date:  2011-11-16       Impact factor: 3.575

3.  An anti-pyroglutamate-3 Aβ vaccine reduces plaques and improves cognition in APPswe/PS1ΔE9 mice.

Authors:  Jeffrey L Frost; Bin Liu; Jens-Ulrich Rahfeld; Martin Kleinschmidt; Brian O'Nuallain; Kevin X Le; Inge Lues; Barbara J Caldarone; Stephan Schilling; Hans-Ulrich Demuth; Cynthia A Lemere
Journal:  Neurobiol Aging       Date:  2015-08-31       Impact factor: 4.673

4.  Phosphorylation of amyloid beta (Aβ) peptides - a trigger for formation of toxic aggregates in Alzheimer's disease.

Authors:  Sathish Kumar; Jochen Walter
Journal:  Aging (Albany NY)       Date:  2011-08       Impact factor: 5.682

5.  Pyroglutamate-Modified Amyloid Beta Peptides: Emerging Targets for Alzheimer´s Disease Immunotherapy.

Authors:  Roxanna Perez-Garmendia; Goar Gevorkian
Journal:  Curr Neuropharmacol       Date:  2013-09       Impact factor: 7.363

6.  Whole-genome characterization in pedigreed non-human primates using genotyping-by-sequencing (GBS) and imputation.

Authors:  Benjamin N Bimber; Michael J Raboin; John Letaw; Kimberly A Nevonen; Jennifer E Spindel; Susan R McCouch; Rita Cervera-Juanes; Eliot Spindel; Lucia Carbone; Betsy Ferguson; Amanda Vinson
Journal:  BMC Genomics       Date:  2016-08-24       Impact factor: 3.969

7.  PI3K activation prevents Aβ42-induced synapse loss and favors insoluble amyloid deposit formation.

Authors:  Mercedes Arnés; Ninovska Romero; Sergio Casas-Tintó; Ángel Acebes; Alberto Ferrús
Journal:  Mol Biol Cell       Date:  2019-12-26       Impact factor: 4.138

Review 8.  Comparative neuropathology in aging primates: A perspective.

Authors:  Carmen Freire-Cobo; Melissa K Edler; Merina Varghese; Emily Munger; Jessie Laffey; Sophia Raia; Selena S In; Bridget Wicinski; Maria Medalla; Sylvia E Perez; Elliott J Mufson; Joseph M Erwin; Elaine E Guevara; Chet C Sherwood; Jennifer I Luebke; Agnès Lacreuse; Mary A Raghanti; Patrick R Hof
Journal:  Am J Primatol       Date:  2021-07-13       Impact factor: 2.371

Review 9.  Focusing the amyloid cascade hypothesis on N-truncated Abeta peptides as drug targets against Alzheimer's disease.

Authors:  Thomas A Bayer; Oliver Wirths
Journal:  Acta Neuropathol       Date:  2014-05-07       Impact factor: 17.088

10.  Pyroglutamate-modified Aβ(3-42) affects aggregation kinetics of Aβ(1-42) by accelerating primary and secondary pathways.

Authors:  C Dammers; M Schwarten; A K Buell; D Willbold
Journal:  Chem Sci       Date:  2017-05-05       Impact factor: 9.825

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.